On this #MeetTheTeamMonday, we would like to highlight Dr. Dennis S. Chi, founder of #TeamOvaryMSK, surgeon extraordinaire, and overall unwavering fighter for women with ovarian cancer.

RT @Moe_ByrneMD: And that’s a wrap on possibly my hardest month of fellowship thus far (hours-wise) but also one of my most rewarding! So l….

RT @leitaomd: Humbled to get this and be a part of such an amazing group of doctors. Can’t make things better alone!! @TeamOvary_MSK @TeamE….

Exciting data for the ovarian cancer community!.The final results of the ARIEL3 Phase 3 trial evaluating #rucaparib as maintenance treatment in platinum-sensitive, recurrent ovarian carcinoma are now published. Read the full study: #ovarian #Cancer #ARIEL3.

RT @YingLiu88: Promising combo of Pembro + Olaparib in p53 aberrant/CN-H #endometrialcancer presented by @MariaRubinstein at #ASCO25! We ne….

RT @YingLiu88: So proud of @saramoufarrij1 who is teaching us all about uterine LMS under the guidance of the one and only #marteehensley!….

RT @JunMaoMD: Get ready for the results our @PCORI funded trial comparing music therapy with cognitive behavioral therapy for anxiety sympt….

RT @MSKCancerCenter: Read more about research from @AliciaLatham10 aimed to investigate the potential of Pap-derived #ctDNA (Pap-ctDNA) as….

RT @YingLiu88: Check out @ariadnaroque8 and her awesome #ASCO25 poster building on work from @TeamOvary_MSK looking at #breastcancer after….

Fantastic work currently being presented @ASCO on a very important topic in #endometrialcancer by @WeillCornell resident Dr. Judy Wang. @YingLiu88 @TeamEndo_MSK.

RT @MSKCancerCenter: 🚨Today kicks off #ASCO25. Follow along on our MSK social channels from May 30-June 3 for onsite updates, and read abou….

Team Ovary’s @VanceBroach would make a fantastic addition to the IGCS Board of Directors. Voting closes June 10, so don’t miss your opportunity to cast your ballot. @TeamOvary_MSK @TeamEndo_MSK . Read more about Dr. Broach and his vision here:.

RT @MSKBiostats: Learning 👩‍🏫from three SCT past presidents and president elect @AlexiaIasonos at #MSKBiostats seminar series. Discussing 💬….

Important new study of prognostic implications of estrogen receptor (ER) expression in no specific molecular profile (NSMP) #endometrial cancer. ER+ was associated with better survival outcomes in the NSMP group. @AmirMomeniBr @TeamEndo_MSK .

For those who were unable to attend the 2025 @ESGO_society meeting earlier this year, please take a look at these highlights with experts in key areas of gynecologic oncology, including @aburustummd discussing fertility preservation. @TeamEndo_MSK .

Fantastic work for a very important clinical trial in patients with #ovarian cancer by @zivanovicmd and team in Heidelberg! @TeamOvary_MSK.

In a new paper @Moe_ByrneMD and team assessed feasibility of identifying mutations (TM) in peritoneal washings in #endometrial cancer. Mutational analysis is feasible, and a substantial subset with suspicious washings had TMs detected. @TeamEndo_MSK .

We were so fortunate to have a fantastic discussion with world-renowned expert Dr. Pei Hui MD PhD regarding diagnosis and management of gestational trophoblastic neoplasia as part of our departmental lecture series program. @TeamOvary_MSK @TeamEndo_MSK

Most uterine carcinosarcomas have detectable TROP2 expression. In an innovative study by @saramoufarrij1 and team, organoid models showed encouraging response to TROP2 targeted antibody drug conjugate sacituzumab govitecan. @TeamOvary_MSK @TeamEndo_MSK .

New paper finding #ovarian low-grade serous tumors with histologic transformation to high grade have both low and high grade morphologic/molecular features, an exception to the dualistic classification in ovarian serous. @Mitosis128 @TeamOvary_MSK .

RT @MSK_DeptOfMed: 🚨The FDA granted accelerated approval to avutometinib & defactinib for adults with KRAS-mutated recurrent low-grade sero….